GWPH

Gw Pharma ADR

Marijuana Industry

The "Pfizer of Medical Marijuana" Could Be In for Another Round of 1,000%+ Gains

Legal marijuana is about more – much more – than recreational use. In fact, its medicinal potential, unchained, could be worth billions more than the billion-dollar consumables market.

Study after study has shown that up to two dozen medical conditions could be treated with marijuana.

Two of its more intriguing components, non-psychoactive cannabidiol (CBD) and psychoactive tetrahydrocannabinol (THC), have a clear impact on brain function and pain management.

Glaucoma sufferers, for example, have long known that pot can reduce ocular swelling. Many people swear by pot's ability to improve lung function, counterintuitive as that may seem. And people suffering from conditions such as multiple sclerosis will tell you that this drug can greatly ease the daily pain they must live with.

Results like those are part of the reason medical marijuana has been approved in 24 states and in many countries around the world – and the reason why the medical marijuana market topped $4 billion in 2015.

Just one company, a biotech that first hit my radar in 2014 and has delivered peak gains of more than 1,100% over the past three years, is favorably positioned to make a classic "corner-the-market" move on this incredibly lucrative segment.

I'm recommending it once more today, after a round of quadruple-digit gains, because I think there's every reason for it to happen all over again...

Marijuana Industry

My Four Biggest Predictions for Cannabis Investing in 2018

It was about a year ago when we first started exploring the world of legal cannabis investing.

At first we looked at, of all things, Microsoft as the world's only mega-cap "pot stock."

Plus, over the past 12 months, we've added Scotts Miracle-Gro, GW Pharmaceuticals, and Insys Therapeutics to our "pot portfolio."

We've followed U.S. Attorney General Jeff Sessions' go-nowhere "war against cannabis" – and President Donald Trump's essential "green light" for medical marijuana. And we've watched legalization efforts in the United States and Canada.

It was also about a year ago that I first published my "weed investors' bible" – The Roadmap to Marijuana Millions. At the time, it was packed with 30 of my absolute favorite plays in the still-booming legal cannabis sector.

Since then, weed investing's only gotten bigger, better, and more profitable.

Over the past year, this section of my Nova-X Report portfolio has seen 10 double-digit winners and eight triple-digit winners… 291% gains… 193.3%… 189.5%…

One recommendation even saw peak gains of 1,588%.

In other words, if you're a Nova-X subscriber who jumped in when I released The Roadmap, you've likely made a mint. And you've probably kept a mint, too, if you closely follow my recommended "free trade" strategy of taking your initial stake off the table and playing with the "house money" every time a stock hands out 100% gains.

Now we want to see what's coming just around the corner.

I expect four watershed events in marijuana investing – four big catalysts… "triggers" – to happen over the next 365 days.

So let's take a look at exactly where I think the biggest profits of 2018 will come from in our "second season" of legal cannabis investing...

marijuana industry

How Orrin Hatch's MEDS Act Would Back Jeff Sessions into a Corner

As Senate President pro tempore, Sen. Orrin Hatch is third in line to the presidency behind Vice President Mike Pence and Speaker of the House Paul Ryan.

And now, he's leading the bipartisan effort to request that Attorney General Jeff Sessions "increase the national marijuana quota in a timely manner to meet the changing medical, scientific, and industrial needs for marijuana."

Here's what that means for the marijuana industry...